MOnoclonal antibodies and potential applications in migraine

Slides:



Advertisements
Similar presentations
The Drug Discovery Process
Advertisements

Introduction to Immunoassays
Use of Monoclonal Antibodies Against Autoimmune Diseases By: Kelly Sambuchi ISAT 351 Spring 1999.
Comparability of a human IgG1 after cell line switching: A retrospective view Peter Lloyd Head of PK-PD, Novartis Biologics.
MLRS 242 Immunology Pat Reed Antibodies
Monoclonal Antibodies Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
“A Fully Caninised Anti-NGF Monoclonal Antibody for Pain Relief in Dogs” Scientific Paper Presentation Madeline Jackson Gearing, D. P., Virtue,
Understanding the Basics of Pharmacology
Clinical Trials in IBD.
Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.
Therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer a.
Anti-therapeutic antibodies Creative Biolabs is a pioneer and undisputed global leader in the rapidly emerging market for therapeutic antibodies. We offer.
Updates in the Clinical Science of CGRP Antagonism for the Treatment of Migraine.
Current and Emerging Treatments for IBD
Dry AMD and GA: The Present and Future
Merkel Cell Carcinoma: What Do Clinicians Need to Know?
Migraine Prevention Therapy: Avoiding Overuse of Medications
A New Era for NOACs:.
THERAPEUTIC Monoclonal Antibodies:
Introduction Antiplatelet Agents ADP Receptor Antagonists.
PCP Perspectives Clinical Considerations in Hyperkalemia
HIV Attachment and Entry: Pursuing a Challenging Target
Immunoglobulin Structure & Function
Strategies for Assessing and Preserving Function in ALS
The Vicious Cycle of Chronic Migraine How Can the Physician Help?
Management of Glioblastoma
Program Introduction. Monoclonal Antibodies and Immunogenicity: Relevance to Clinical Practice?
Basics of Immunotherapy Potential Therapeutic Targets.
Translating Atopic Dermatitis
Diagnostic and Management Challenges in Patients With Chronic Migraine
Results w the CI.
Atopic Dermatitis. Introduction to a Clinical Course On New Developments In Atopic Dermatitis.
Principles of Comparative Effectiveness in PsA and AS
C. J. Ilse Raats, Jacob Van Den Born, Jo.H.M. Berden, M.D., Ph.D. 
Figure 3 Strategies to achieve therapeutic inhibition of IL-1
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Demystifying the Science of Monoclonal Antibodies in Migraine
Histamine H1 receptor antagonist
CGRP Antibodies in Migraine
Emerging Frontline Treatments for Patients With Hodgkin Lymphoma
Current and Future Perspectives on Migraine Prevention Therapy
Personalized Therapy in Relapsed or Refractory CLL
Advancing the Treatment of IBD With Biologics
Hiding in Plain Sight: How Cancer Evades the Immune System
Breaking New Ground With Migraine Prevention Therapies
Getting to Grips With the Science of CGRP and Migraine
New Classes of Therapy in Multiple Myeloma
Monoclonal Antibodies in CVD: What Does the Future Hold?
The Rising Cost of Healthcare and Potential Impact of Biosimilars
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.
Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.
Patient and Clinician Perspectives on Preventive Therapy for Migraine
THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES
Pathogenesis of IBD, and the Role of Biologic Therapies
A Closer Look.
Raptiva efalizumab Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons.
Migraine Therapeutics in Development
Patient and Clinician Perspectives on Preventive Therapy for Migraine
The Glutamate Pathway.
Rheumatoid Arthritis.
Diagnostic Criteria Migraine Without Aura
Empowering Patients and Prescribers to Improve Treatment Adherence in Schizophrenia.
US Army Medical Research and Materiel Command
Widening the Options for Major Depressive Disorder
Monoclonal Antibodies in Migraine Prevention: What the Primary Care Physician Needs to Know.
A New Era in Migraine Prevention
Risk Factors for Migraine Chronification
Foundations of Asthma.
Psoriatic Arthritis.
Presentation transcript:

MOnoclonal antibodies and potential applications in migraine

Introduction to mAbs

What Is CGRP and What Is Its Function?

CGRP Receptor Antagonists in Migraine

mAb Development: History

Evolution of Therapeutic mAbs

Normal Antibody Production

What Is an Antibody?

Five Different Antibody Isotypes in Humans

Antibody Types

Antibodies and IgG

IgG Subclasses

Therapeutic mAbs

Polyclonal Antibodies vs mAbs

Naming Conventions for mAbs

Naming Conventions for Therapeutic mAbs: Species

Therapeutic mAbs: Direct and Indirect Mechanisms of Action

mAb Metabolism and Elimination

FcRn and Antibody Half-life

Pharmacokinetics of mAbs

Tolerability of mAbs

Benefits of mAbs

mAbs vs Small Molecules

CGRP

CGRP Receptor Mechanisms

CGRP and Its Related Receptor Family

Antibody Binding to Receptor Complex

Specificity of Anti-CGRP Pathway mAbs

Small-Molecule CGRP Antagonists vs mAbs

New CGRP Antibody Antagonists

Anti-CGRP Pathway mAbs in Development: Characteristics

Efficacy and Tolerability of Anti-CGRP Pathway mAbs in Phase 2 Studies

Summary of Efficacy and Tolerability in Phase 2 Trials

Concluding Remarks

Abbreviations

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.